Showing 901-910 of 1059 results for "".
- Norepinephrine Reuptake Inhibitor Treatment Significantly Reduced Cataplexy Attacks in People with Narcolepsy Type 1https://practicalneurology.com/news/nri-therapy-significantly-reduced-cataplexy-attacks-in-people-with-narcolepsy-type-1/2473965/Treatment with AXS-12 (reboxetine; Axsome, New York, NY), a highly selective norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator, was associated with significant reductions in cataplexy attacks in people with narcolepsy type 1 (NT1), according to results from the phase 3 SYMPH
- Stem Cell Therapy Reduced Brain Atrophy in People with Mild Alzheimer Diseasehttps://practicalneurology.com/news/stem-cell-therapy-reduced-brain-atrophy-in-people-with-mild-alzheimer-disease/2473818/The intravenous (IV) treatment of people with mild Alzheimer disease (AD) using Lomecel-B (laromestrocel; Longeveron, Miami, FL), a bone-marrow–derived allogeneic mesenchymal stem cell (MSC), was associated with reduced atrophy of the whole brain and hippocampus compared with placebo. These
- Research Leaders Recognized at the 2025 MDA Clinical & Scientific Conferencehttps://practicalneurology.com/news/research-leaders-recognized-at-the-2025-mda-clinical-scientific-conference/2473814/The Muscular Dystrophy Association (MDA) recognized 2 legacy award recipients at the 2025 MDA Clinical & Scientific Conference. The awardees were honored based on their significant contributions to clinical research and community advocacy. The 2025 MDA Legacy Award for Achie
- Diagnosis and Care Recommendations for Limb-Girdle Muscle Dystrophy 2I/R9 Presentedhttps://practicalneurology.com/news/diagnosis-and-care-recommendations-for-limb-girdle-muscle-dystrophy-2ir9-presented/2473813/Draft standard of care (SoC) guidelines for the diagnosis and management of people with limb-girdle muscle dystrophy 2I/R9 (LGMDR9) were presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. According to the presenters of the draft SoC, the guidelines ar
- Gene Therapy Shown to Improve Motor Ability for Children with SMAhttps://practicalneurology.com/news/gene-therapy-shown-to-improve-motor-ability-for-children-with-sma/2473812/Treatment with OAV101 IT (intrathecal onasemnogene abeparvovec; Novartis, Cambridge, MA) was associated with significant improvements in motor ability when administered to children with spinal muscular atrophy type 2 (SMA 2). Top-line results of the phase 3 STEER clinical study (NCT05089656) pres
- Parafoveal OCT Scans Show Promise as Biomarker of MS Progressionhttps://practicalneurology.com/news/parafoveal-oct-scans-show-promise-in-assessing-ms-progression/2473798/Anatomical variations of parafoveal retinal layer thickness measured using optical coherence tomography (OCT) were associated with clinical outcomes in individuals with multiple sclerosis (MS) according to study results presented at the Americas Committee for Treatment and Research in Multiple Sc
- Radiprodil Designated a Breakthrough Therapy for GRIN-Related Neurodevelopmental Disorderhttps://practicalneurology.com/news/radiprodil-designated-a-breakthrough-therapy-for-grin-related-neurodevelopmental-disorder/2473793/Radiprodil (GRIN Therapeutics, New York, NY), a selective, potent negative allosteric modulator of the N-methyl-D-aspartate receptor subtype SB (NR2B or GluN2B), has been granted Breakthrough Therapy designation by the Food and Drug Administration (FDA) for the treatment of seizures associated wi
- Long-Term Seizure Reduction Seen with 5-HT2C Receptor Superagonist Treatment in Those with DEEshttps://practicalneurology.com/news/treatment-with-bexicaserin-associated-with-seizure-frequency-reduction-for-people-with-developmental-and-epileptic-encephalopathies/2473786/Treatment of seizures using bexicaserin (Lundbeck, Deerfield, IL) was associated with improved long-term efficacy, safety, and tolerability outcomes for individuals with developmental and epileptic encephalopathies (DEEs) in the results of a 12-month open-label extension (OLE) study. Individuals
- Beta-Blocker Shows Promise in Reducing Stroke Risk for Women with Migrainehttps://practicalneurology.com/news/beta-blocker-shows-promise-in-reducing-stroke-risk-for-women-with-migraine/2473779/Treatment with propranolol for women with migraine may reduce risk of stroke, according to findings from a preliminary study of 3 million electronic health records (EHRs) presented at the American Stroke Association’s International Stroke Conference 2025. Propranolol, a nonselective beta-bl
- Biomarker Testing May Accelerate Synucleinopathy Diagnosis According to New CNSA White Paperhttps://practicalneurology.com/news/biomarker-testing-may-accelerate-synucleinopathy-diagnosis-according-to-new-cnsa-white-paper/2473772/The emergence of new biomarker tests may enable earlier detection and treatment of symptoms associated with synucleinopathies according to a new comprehensive Clinical Proceedings White Paper published by the Clinical Neurological Society of America (CNSA). The White Paper, titled &ldqu